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Background: Human T cell lymphotropic virus type 1 (HTLV-1) infection can lead to development of adult T cell
leukemia/lymphoma (ATL) or HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in a subset of
infected subjects. HTLV-1 basic leucine zipper factor (HBZ) gene has a critical role in HTLV-1 infectivity and the
development of ATL and HAM/TSP. However, little is known about the immune response against HBZ in HTLV-1
-infected individuals. In this study, we examined antibody responses against HBZ in serum/plasma samples from
436 subjects including HTLV-1 seronegative donors, asymptomatic carriers (AC), ATL, and HAM/TSP patients using
the luciferase immunoprecipitation system.
Results: Immunoreactivity against HBZ was detected in subsets of all HTLV-1-infected individuals but the test did
not discriminate between AC, ATL and HAM/TSP. However, the frequency of detection of HBZ-specific antibodies in
the serum of ATL patients with the chronic subtype was higher than in ATL patients with the lymphomatous
subtype. Antibody responses against HBZ were also detected in cerebrospinal fluid of HAM/TSP patients with
anti-HBZ in serum. Antibody responses against HBZ did not correlate with proviral load and HBZ mRNA expression
in HAM/TSP patients, but the presence of an HBZ-specific response was associated with reduced CD4+ T cell
activation in HAM/TSP patients. Moreover, HBZ-specific antibody inhibited lymphoproliferation in the PBMC of
HAM/TSP patients.
Conclusions: This is the first report demonstrating humoral immune response against HBZ associated with HTLV-I
infection. Thus, a humoral immune response against HBZ might play a role in HTLV-1 infection.
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Human T cell lymphotropic virus 1 (HTLV-1) infects 20
million people worldwide [1]. While the majority of
infected individuals are asymptomatic carriers (AC) of
the virus, 5-10% of infected people develop either adult
T cell leukemia/lymphoma (ATL) [2] or a chronic, pro-
gressive, neurological disease termed HTLV-1-associated
myelopathy/tropical spastic paraparesis (HAM/TSP)
[3,4]. HAM/TSP is characterized by perivascular inflam-
matory infiltrates in the brain and spinal cord, with a* Correspondence: JacobsonS@ninds.nih.gov
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distribution, and reproduction in any mediumpredominance of HTLV-1-specific CD8+ T cells [5,6].
High frequencies of these effector cells have been
demonstrated in peripheral blood with even higher fre-
quencies in cerebrospinal fluid (CSF) of patients with
HAM/TSP [7-9], and robust humoral responses against
HTLV-1 antigens that can be detected in the CSF as well
as the serum [4,10]. While the cellular and humoral im-
mune responses against HTLV-1 play crucial, protective
roles in HTLV-1 infection, chronically activated immune
responses have been suggested to underlie the pathogen-
esis of HAM/TSP [11]. Therefore, characterization of
HTLV-1-specific immune responses may provide evidence
of immune dysregulation during disease progression inCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.












Male 15 [20.5] 22 [16.5] 41 [46.1] 13 [26.5]
Female 58 [79.5] 111
[83.5]
48 [53.9] 36 [73.5]
Race (n[%])
African-descent 72 [98.6] 132
[99.2]
86 [96.6] 42 [85.7]
Caucasian-
descent
0 [0.0] 0 [0.0] 0 [0.0] 1 [2.0]
Other 0 [0.0] 1 [3.0] 0 [0.0] 2 [4.1]
Missing 1 [1.4] 3 [3.4] 4 [8.2]
Age†
Mean ± s.e.m. 38.5 ± 1.5 42.2 ± 1.2 45.5 ± 1.7 47.4 ± 1.8









Male 19 [76.0] 3 [25.0] 17 [30.9]
Female 11 [24.0] 9 [75.0] 38 [69.1]
Race (n[%])
African-descent 11 [44.0] 5 [41.7] 36 [65.5]
Caucasian-
descent
11 [44.0] 5 [41.7] 14 [25.5]
Other 3 [12.0] 2 [16.6] 5 [9.1]
Age
Mean ± s.e.m. 45.6 ± 2.4 58.9 ± 3.6 51.75 ± 1.5
Range (24 – 73) (36 – 75) (25 – 75)
†Information on age was missing for 1 HAM/TSP subject from
Jamaican cohort.
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notherapeutic targets in HTLV-1-related diseases.
Despite strong HTLV-1-specific immune responses,
HTLV-1 proviral loads are significantly elevated in HAM/
TSP patients compared to AC [12]. Increased expression
particularly of the trans-activating viral gene encoding
HTLV-1 Tax induces the expression of various cellular
genes, including IL-2, IL-15, and their receptors [13-16],
which directly contributes to lymphocyte activation in
HAM/TSP patients [9,17]. A novel gene, HTLV-1 basic
leucine zipper factor (HBZ), encoded by the minus strand
of the HTLV-1 proviral genome has been identified [18].
HBZ mRNA is ubiquitously expressed in all ATL cells and
promotes the growth and survival of the leukemic cells
[19]. HBZ protein was found to inhibit Tax-mediated viral
gene transcription from the 5’ LTR and to selectively sup-
press the classical NF-κB pathway [18,20-23]. Previous
in vivo studies also demonstrated that HBZ expression
enhanced HTLV-1 infectivity, T cell proliferation and
lymphoma [24-26]. Furthermore, HBZ mRNA expression
was detected in HAM/TSP patients, and was correlated
with proviral load and disease severity [27]. Since these
findings suggested that HBZ has a critical role in HTLV-1
persistence and the development of ATL and HAM/TSP,
it is important to define HBZ-specific immune responses
in HTLV-1-infected individuals.
Recent evidence has shown that HBZ is an immuno-
genic protein recognized by HBZ-specific CTL clones
[28,29]. HBZ-specific CD8+ T cells are detected in AC
and HAM/TSP patients, and HBZ-specific CTL clones
were able to lyse naturally infected cells isolated from
AC and HAM/TSP patients, but not ATL patients
[28,29]. Despite recent studies on HBZ-specific cellular
immune responses, there are no reports on the humoral
immune responses to HBZ. We recently reported that a
luciferase immunoprecipitation system (LIPS), a highly
sensitive, quantitative technology, could efficiently detect
HTLV-1 antigen-specific antibody responses in serum of
HTLV-1-infected individuals [30,31]. Since the LIPS assay
can detect antibody responses against multiple antigens,
profiling of HTLV-1-specific antibody responses using
LIPS demonstrated a differential pattern of antibody
responses for HTLV-1 Gag, Env and Tax between HTLV-
1-infected and uninfected subjects as well as between the
AC and ATL and HAM/TSP patients [30,31]. Here we
optimized the LIPS assay for detection of immunoreactiv-
ity against HBZ, and first determined antibody responses
against HBZ in HTLV-1-infected individuals.
Results
Characteristics of the study population
The demographic characteristics of the study groups are
summarized in Table 1. Among Jamaican subjects, the
mean ages of the study groups varied from 38 years ofage in the HTLV-1-seronegative donor (ND) group to 47
years in the HAM/TSP group (p = 0.0003). The majority
of each group was comprised of females, although the
proportion of females in each group ranged from 53.9%
in the ATL group to 83.5% in the AC group (p < 0.0001).
All the study groups were predominantly of African-
descent. Among the NIH subjects, the mean ages of the
study groups varied from 45 years in the ND group to
58 years in the AC group (p = 0.0052). The proportion of
females in each group ranged from 24.0% in the ND
group to 75.0% in the AC group (p = 0.0074). The pro-
portion of African-descent and Caucasian-descent were
equal in the ND and the AC group; there were slightly
more individuals of African-descent in the HAM/TSP
group.
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Antibody responses for HBZ were analyzed in the separ-
ate groups of Jamaican and NIH subjects. There were no
significant differences in frequency or magnitude of anti-
HBZ antibody responses in serum/plasma between
Jamaican and NIH subjects (data not shown) so they
were combined in the remaining analyses, yielding a
total of 436 serum/plasma samples obtained from ND,
AC, ATL patients and HAM/TSP patients. Strong mean
antibody levels against HBZ were detected in the HTLV-1
-infected groups, including AC, ATL patients and HAM/
TSP patients, compared to the ND group (Figure 1A and
Table 2). Although the mean antibody level against HBZ
among the ATL subjects did not differ significantly from
those of the ND group, the differences of the mean anti-
body level were statistically significant for the AC and
HAM/TSP groups relative to the ND group (Figure 1A).
Within each HTLV-1-infected group, robust anti-HBZ
antibody responses (209751.9-1180625.0 LU) were
observed in subsets of individuals, but among the
HTLV-1-infected groups, the mean anti-HBZ antibody
levels were not significantly different (Figure 1A).
When the data were analyzed as the percent of positive
responders above a negative threshold (6853 LU; dot-
ted line in Figure 1A), immunoreactivity against HBZ
was detected in 10.34% (15/145) of AC, 12.36% (11/89)
of ATL patients, and 13.46% (14/104) of HAM/TSP



















































Figure 1 Antibody responses against HBZ from serum/plasma of ND,
antibody responses against HBZ in serum/plasma of ND, AC, ATL and HAM
98 ND, 145 AC, 89 ATL patients and 104 HAM/TSP patients. Antibody respo
and HAM/TSP). The horizontal line represents the mean. Dotted line repres
response against HBZ in serum/plasma of ND, AC, ATL and HAM/TSP patie
among the groups was compared by Chi-Square Test. (C) Comparison of a
subtypes using Mann–Whitney Test. The data were obtained from 30 acute
represents the mean. Dotted line represents cut-off value (6853LU). (D) Fre
ATL patients. The distribution of subjects with antibody response against Himmunoreactivity in each of the HTLV-1-infected
groups was significantly higher than the ND group, but
again there were no statistically significant differences
between the HTLV-1-infected groups (Figure 1B). In
addition, the Four-Way Analysis of Variance (ANOVA)
model with interactions using race, gender, age and
study group as factors showed no significant differ-
ences of the level of immunoreactivity against HBZ by
gender, race and age between each study group (data
not shown). There were also no significant differences
in the frequency of immunoreactivity against HBZ by
gender, race and age between each study group (data
not shown).
Since HBZ has been suggested to play a role in ATL, and
ATL patients can be divided into the predominant clinic-
ally unique subtypes (acute, chronic or lymphoma), it was
of interest to determine if serum anti-HBZ responses could
discriminate among these subtypes. The mean anti-HBZ
antibody levels were not significantly different among the
ATL subtypes (Figure 1C). However, the prevalence of
HBZ immunoreactivity was detected in 10.0% (3/30) of
ATL patients with the acute subtype, 24.14% (7/29) of
those with the chronic subtype, and 3.33% (1/30) of those
with the lymphoma subtype, demonstrating that ATL
patients with the chronic subtype showed significantly
higher anti-HBZ prevalence compared to ATL patients
with the lymphoma subtype (Figure 1D and Table 2). Col-























AC, ATL patients and HAM/TSP patients. (A) Comparison of
/TSP patients using Mann–Whitney Test. The data were obtained from
nses against HBZ were detected in HTLV-1-infected groups (AC, ATL
ents cut-off value (6853LU). (B) Frequency of subjects with antibody
nts. The distribution of subjects with antibody response against HBZ
ntibody responses against HBZ in serum of ATL patients by ATL
, 29 chronic and 30 lymphoma ATL patients. The horizontal line
quency of subjects with antibody response against HBZ in serum of
BZ among the groups was compared by Chi-Square Test.













Mean 626.5 27102 8112 38413
Median 99.0 375.9 256.6 692.2
Range (0–6853) (0–1180625) (0–
281419)
(0–815217)
St. dev. 1048 132838 37168 135893
Number of anti- 0 15 11 14
HBZ + subjects
(%)*








Lymphoma (n = 30)
Anti-HBZ
Mean 7967 13413 3132
Median 165.1 535.0 166.0
Range (0–201062) (0–281419) (0–75697)
St. dev. 36592 51994 13753




^Data includes both Jamaican and NIH cohort.
* Cut off value: 6853LU (100% percentile of ND).
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related diseases, had immunoreactivity against HTLV-1
HBZ.
Antibody responses against HBZ did not correlate with
those for Gag, Env and Tax, and HTLV-1 infection
Since HBZ-specific immunoreactivity was detected in a
subset of HTLV-1 infected subjects, we asked whether
there is any relationship between HBZ-specific immunor-
eactivity and other immunological and virological markers
of HTLV-1 infection, such as antibody responses to other
HTLV-1 proteins and HTLV-1 viral gene expression. Anti-
body responses against Gag, Env or Tax did not differ
significantly between HTLV-1-infected individuals with or
without HBZ-specific immunoreactivity (Figure 2A-C).
We also compared HTLV-1 proviral load and HBZ mRNA
expression between HTLV-1-infected individuals with and
without HBZ-specific immunoreactivity. Since PBMC were
unavailable for the Jamaican subjects, cells were obtained
from NIH HAM/TSP patients whose serum was tested
for anti-HBZ antibody responses. These 13 HAM/TSP
patients showed a range of HTLV-1 proviral loads in
PBMCs between 5.6 and 87.8% (Figure 2D). Consistentwith a previous report [27], HBZ mRNA was detectable in
PBMCs of HAM/TSP patients and significantly correlated
with proviral loads (Figure 2D). There was no significant
difference of proviral loads between individuals with and
without HBZ-specific immunoreactivity (Figure 2E); there
was also no significant correlation between proviral load
and the HBZ-specific antibody responses (Figure 2G).
Moreover, the mean expression of HBZ mRNA from
HAM/TSP patients’ PBMC was not associated with the de-
tection of HBZ immunoreactivity (Figure 2F) or magnitude
of serum anti-HBZ antibodies (Figure 2G). Thus, antibody
responses for HBZ did not correlate with proviral loads or
HBZ mRNA expression in HAM/TSP patients, consistent
with previous studies that also failed to demonstrate a cor-
relation between HBZ mRNA expression and HTLV-1
antibody titer in serum [27].
Antibody responses against HBZ in CSF
Since strong antibody responses against HTLV-1 anti-
gens have been reported in both serum and CSF of
HAM/TSP patients [10,32], we also examined antibody
responses for HTLV-1 Gag, Env, Tax and HBZ in both
serum and CSF samples of HAM/TSP patients with or
without HBZ-specific antibody responses. Antibody
responses for Gag, Env and Tax were detected in both
serum and CSF samples of all five HAM/TSP patients
(Figure 3A-C). Antibody responses for HBZ were only
detected in CSF samples of HAM/TSP patients (#1 and
#2) with HBZ-specific antibody responses in serum, but
not in HAM/TSP patients (#5, #6 and #7) who were
negative for HBZ-specific immunoreactivity in serum
(Figure 3D). Moreover, HBZ-specific antibody responses
in CSF were detected at lower levels compared to serum
(Figure 3D). Comparison of antibody responses between
CSF and serum revealed that the ratio of anti-HBZ anti-
body in CSF to serum was lower than the ratio of anti-
Gag, anti-Env and anti-Tax in CSF to serum (Figure 3E).
A role of HBZ-specific antibody in HTLV-1 infection
Since HBZ is involved in both regulation of viral gene
transcription and T-cell proliferation [18,20-23], we asked
whether HBZ-specific antibody responses have potentially
beneficial roles in suppressing immune activation in
HAM/TSP patients. To confirm the inhibitory effect of
HBZ-specific antibody on T cell activation, we further
attempted to generate immortalized memory B cells pro-
ducing HBZ-specific antibody from HAM/TSP patients
and isolate the specific antibody from the B cell culture
supernatants. Production of HBZ-specific antibodies was
detected in 9.2-41.4% of immortalized memory B cell cul-
tures from all three HAM/TSP patients with HBZ-specific
antibody response (#1, #3 and #4; Figure 4A). As control,
HTLV-I-specific antibodies to Gag, Env and Tax were also
able to be detected in memory B cell pools of both HAM/
A B C
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Figure 2 Comparison of antibody responses against HTLV-1, proviral loads and HBZ mRNA expression of HTLV-1-infected individuals.
Comparison of antibody responses against Gag (A), Env (B) and Tax (C) in serum/plasma of HTLV-1-infected individuals with and without
antibody response against HBZ by Mann–Whitney Test. The data were obtained from 338 HTLV-1-infected individuals; 145 AC, 89 ATL patients
and 104 HAM/TSP patients. Anti-HBZ (−) group includes 130 AC, 78 ATL patients and 90 HAM/TSP patients. Anti-HBZ (+) group includes 15 AC,
11 ATL patients and 14 HAM/TSP patients. The horizontal line represents the mean. (D) Correlation of HTLV-1 proviral load with HBZ mRNA
expression in 13 HAM/TSP patients including 6 patients with antibody response against HBZ (closed circles) and 7 patients without antibody
response against HBZ (closed triangles) by Spearman’s correlation test. (E) Comparison of HTLV-1 proviral loads between HAM/TSP patients with
and without antibody response against HBZ. HTLV-1 proviral loads were examined in PBMCs of HAM/TSP patients using Mann–Whitney Test. The
horizontal line represents the mean. (F) Comparison of HBZ mRNA expression between HAM/TSP patients with and without antibody response
against HBZ. The expression of HBZ mRNA was examined in PBMCs of HAM/TSP patients using Mann–Whitney Test. The horizontal line
represents the mean. (G) Correlation of immunoreactivity against HBZ with HTLV-1 proviral loads (closed circles) and HBZ mRNA expression
(opened circles) in 6 HAM/TSP patients with antibody response against HBZ by Spearman’s correlation test.
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sponse, but HBZ-specific antibody production was not
detected in the memory B cell cultures of HAM/TSP
patients without HBZ-specific antibody response (data not
shown). To confirm the reactivity of HBZ-specific anti-
body produced from memory B cells, we examined HBZ
protein detection using an anti-HBZ (+) B cell culture
supernatant by western blot. The nuclear proteins were
extracted from HTLV-1-uninfected (Jurkat and MOLT-3)
and infected cell lines (MT-2 and HUT102) and HBZ/
pRen2-untransfected and transfected 293 T cells. As
shown in Figure 4 Bi, HBZ protein (25 kDa) and HBZ-
Renilla luciferase (Ruc) fusion protein (61 kDa) was
detected in nuclear protein extract of HTLV-1 infected
cell lines (MT-2 and HUT102) and HBZ/pRen2 trans-
fected 293T cells, respectively, using anti-HBZ (+) B cell
culture supernatant. Rabbit anti-HBZ serum was used as a
positive control and also reacted with the HBZ protein
and HBZ-Ruc fusion protein similar to the anti-HBZ (+) B
cell culture supernatant (Figure 4 Bi and ii). Furthermore,
we isolated HBZ-specific IgG from supernatants of amemory B cell culture from HAM/TSP patient (#1), and
examined the inhibitory effect on spontaneous lympho-
proliferation in PBMCs of HAM/TSP patients without
anti-HBZ response. The representative dot plots showed
the inhibition of spontaneous proliferation by HBZ-
specific IgG in PBMCs of a HAM/TSP patient without
anti-HBZ response (Figure 4C). As shown in Figure 4 Di,
HBZ-specific IgG significantly inhibited the spontaneous
lymphoproliferation predominantly in CD8+ T cells of
HAM/TSP patients without anti-HBZ response. Since
CD4+ T cells of HAM/TSP patients showed significantly
less proliferation than CD8+ T cells, it was difficult to ob-
serve an inhibitory effect of HBZ-specific IgG on CD4+ T
cell proliferation in HAM/TSP patients without anti-HBZ
response (Figure 4 Dii). Consistent with previous reports
[33], the frequency of CD4+CD25+ T cells was higher in
HAM/TSP patients without anti-HBZ antibody responses
than those of ND, but HAM/TSP patients with anti-HBZ
antibody responses showed significantly less CD4+CD25+ T
cells compared to patients without anti-HBZ antibody
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Figure 3 Detection of antibody responses against HTLV-1 in serum and CSF of HAM/TSP patients. The data were obtained from 5 HAM/
TSP patients including 2 patients (#1 and #2) and 3 patients (#5, #6 and #7) with and without HBZ-specific antibody response, respectively.
Antibody responses for Gag (A), Env (B), Tax (C) and HBZ (D) were examined in serum (opened bar) and in CSF (closed bar). (E) Ratio of
immunoreactivities against HTLV-1 Gag, Env, Tax and HBZ in CSF to those in serum of two HAM/TSP patients with HBZ-specific
antibody responses.
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nificantly higher frequency of CD25+ cells than those of
NDs (Figure 4 Eii). The frequency of CD8+CD25+ T cells
was less in HAM/TSP patients with anti-HBZ response
than those of patients without anti-HBZ response and
approached significance (P = 0.0553; Figure 4 Eii). These
results demonstrate that HBZ-specific antibody responses
may have a role in suppressing T cell activation in HAM/
TSP patients.
Discussion
The HBZ gene is constitutively expressed in HTLV-1
-infected cells, ATL cells and PBMC of HTLV-1-infected
individuals [19,27,34] and is thought to be involved in
both regulation of viral gene transcription and T-cell
proliferation [18,20-23], suggesting that HBZ has a crit-
ical role in HTLV-1 infectivity and the development of
HTLV-1-related diseases [24-27]. Therefore, it is import-
ant to define HBZ-specific immune responses in HTLV-
1-infected individuals. In this study, we screened 436
serum/plasma samples from Jamaica and the United
States, including NDs, ACs, ATL and HAM/TSP
patients, and first defined the humoral immune response
to HBZ in HTLV-1-infected individuals. The resultsdemonstrated that antibody responses for HBZ were
detected in 11.8% of HTLV-1-infected individuals. The
frequency of antibody response for HBZ was low com-
pared to a high frequency of antibody responses for Gag,
Env and Tax (99.3%, 92.3% and 93.0%, respectively) as
previously described [31]. Recently, it was reported that
HBZ-specific CD8+ T cells were detected in HTLV-1
-infected individuals, and HBZ-specific CTL clones were
able to lyse naturally infected cells [28,29]. Likewise, it
was demonstrated that the predicted binding affinity of
HLA molecules to HBZ peptides is significantly weaker
than that of Tax peptides and that the frequency of
HBZ-specific CD8+ T cells is significantly lower than the
frequency of Tax-specific CD8+ T cells [29]. Our results
support previous reports [28,29] suggesting that HBZ is
an immunogenic protein although HBZ-specific immune
responses appear to be lower compared to the other
HTLV-1 immunodominant proteins, Gag, Env and Tax.
Moreover, HBZ-specific humoral immune responses did
not show any association with HTLV-1-related disease
outcomes, while HTLV-1-infected AC and ATL patients
from HAM/TSP patients could be discriminated based on
the differential antibody responses for Gag, Env and Tax
[31]. ATL patients showed lower mean immunoreactivity
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Table 2). This is consistent with our previous report that
ATL patients demonstrated lower levels of antibody
responses to all three HTLV-1 immunodominant proteins,





































10 5 9.8 21
654.16
































































































Figure 4 (See legend on next page.)This may be a consequence of a more global immunosup-
pressed state in ATL than HAM/TSP [35]. Interestingly,
the distribution of an HBZ-specific antibody response by
ATL subtype demonstrated that immunoreactivity against
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Figure 4 Inhibitory effects of HBZ-specific antibody on T cell activation of HAM/TSP patients. (A) Detection of immortalized memory B
cells producing HBZ-specific antibodies in HAM/TSP patients. The immortalized B cells were generated from three HAM/TSP patients with
anti-HBZ in serum, and production of HBZ-specific antibodies (closed bars) was detected using LIPS assay. (B) Detection of HBZ proteins using an
anti-HBZ (+) B cell culture supernatant and rabbit anti-HBZ serum by western blot. The nuclear proteins were extracted from HTLV-1-uninfected
(Jurkat and MOLT-3) and HTLV-I-infected (MT-2 and HUT102) cell lines and HBZ/pRen2-untransfected and transfected 293T cells. Detection of HBZ
proteins was confirmed by western blot (i) representative image and (ii) the intensity of HBZ proteins. (C) Representative dot plots of CFSE
staining in CD8+ T cells of a HAM/TSP patient with HBZ-specific antibody or control IgG after culture for 6 days. (D) Inhibitory effects of
HBZ-specific antibody on spontaneous proliferation of CD8+ T cells (i) and CD4+ T cells (ii) in PBMCs of HAM/TSP patients after culture for 6 days
by Wilcoxson matched-pairs signed rank test. The data were obtained from 7 HAM/TSP patients without anti-HBZ response (closed circles) and
one ND (opened circle) as control. (E) Comparison of frequencies of CD4+CD25+ T cells (i) and CD8+CD25+ T cells (ii) of NDs, HAM/TSP patients
with and without antibody responses for HBZ by Mann–Whitney test. The data were obtained from twelve NDs, and five and ten HAM/TSP
patients with and without antibody responses for HBZ, respectively. The horizontal line represents the mean.
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ference in the HBZ-specific antibody responses between
patients with the chronic and lymphoma subtypes
(Figure 1D). The median survival of patients with ATL is
20 weeks; patients with the acute subtype survive for a
median of 13 weeks, patients with the lymphoma subtype
survive for a median of 20 weeks, and patients with the
chronic subtype survive for a median of 25 weeks [36].
The diagnostic criteria and clinical classification of the
chronic ATL subtype includes more absolute lymphocytes
with T lymphocytosis, and is associated with a better prog-
nosis compared to the acute and lymphoma ATL subtypes
[37]. Therefore, our results suggest that a subset of ATL
patients generate HBZ-specific immune response (of low
magnitude), which may delay disease progression. Since
previous reports did not show any significant differences
in antibody responses for HTLV-1 Gag, Env and Tax
among ATL subtypes [31], it is important to validate these
observations with HBZ in a larger sample of ATL patients
that includes the less common subtype, smoldering ATL.
In addition, since high expression of HBZ mRNA has
been reported in ATL cells [19], it would be of interest to
correlate anti-HBZ antibody responses with levels of HBZ
mRNA. Unfortunately, PBMCs from ATL patients in this
study were not available for analysis.
The lack of correlation of antibody responses for HBZ
with proviral loads or HBZ mRNA expression might par-
tially be the result of virological properties of HBZ itself. It
has been reported that HBZ mRNA was detectable in
PBMCs of HAM/TSP and ATL patients after culture, but
mainly remains retained in the nucleus more than in the
cytoplasm [38]. In primary ATL cell lines, only the spliced
form of HBZ protein was detected in the nuclear fraction
[39]. These reports suggest that persistence of HTLV-1
might be a consequence of reduced HBZ translation or
limited localization of HBZ protein, and perhaps of
reduced exposure of infected cells to HBZ-specific host
immune responses. In other retrovirus infections such as
human immunodeficiency virus (HIV), the regulatory
protein Tat plays an important role in viral infectivity and
pathogenicity [40], however Tat-specific antibody res-ponses are detected only in a small number of HIV-
infected individuals [41]. Similarly, antibody responses for
HBZ were only observed in a subset of HTLV-1-infected
individuals. Genetic factors, such as HLA, may also play a
role in generation of a specific immune response, but lar-
ger numbers of HTLV-1-infected individuals with HBZ-
specific humoral immune response will be required to fur-
ther characterize the humoral immune response against
HBZ in HTLV-1-associated diseases.
Antibody responses for HTLV-1 Gag, Env and Tax were
elevated both in serum and CSF of HAM/TSP patients
(Figure 3), consistent with previous reports [10,32]. By
contrast, HBZ-specific antibody responses were only
detected in CSF of HAM/TSP patients if there was a coin-
cident serum antibody response against HBZ. These
virus-specific antibodies in the CSF are either derived
from the blood (leakage through the blood–brain-barrier)
or alternatively, are synthesized locally within the CNS.
Interestingly, the ratio of HBZ-specific antibody responses
in CSF to serum was lower compared to ratios of antibody
responses for HTLV-1 Gag, Env and Tax in CSF to serum
(Figure 3). These results suggest that HBZ-specific anti-
body in the CSF is derived from the blood while anti-
bodies for HTLV-1 Gag, Env and Tax are intrathecally
synthesized. It has been previously reported that intra-
thecal antiviral antibody synthesis was confirmed by the
presence of HTLV-1-specific antibodies and oligoclonal
IgG in CSF [42-45] and that the lack of intrathecal anti-
body response to HTLV-1 in HAM/TSP correlates with
higher proviral loads and worse outcome [46]. In the fu-
ture it will be interesting to examine the relationship
between CSF proviral load, and the presence or level of
anti-HBZ antibody in CSF and to compare the clinical
phenotype of HAM/TSP patients with and without CSF
anti-HBZ antibodies.
Lastly, to further confirm the presence and the function
of HBZ-specific antibody, we generated memory B cells
producing HBZ-specific antibody from HAM/TSP patients
with antibody response against HBZ. Since antigen-specific
human memory B cells circulate at very low frequencies
in peripheral blood, many researchers have relied on
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antibody-secreting cells by in vitro culture or develop-
ment of alternative strategies [47-52]. In the present
study, HBZ-specific antibody production was detected in
memory B cells generated from all HAM/TSP patients
who had antibody responses for HBZ in serum. As con-
trol, HBZ-specific antibody production was not detected
in memory B cell cultures generated from HAM/TSP
patients without HBZ-specific antibody response, while
memory B cells generated from both HAM/TSP patients
with and without HBZ-specific antibody response could
produce antibodies specific to HTLV-I Gag, Env or Tax
(data not shown). These results suggested that HTLV-1
-specific memory B cells are maintained through an indi-
vidual’s lifetime at levels that correlate with sustained
serum antibody concentrations. Moreover, HBZ-specific
antibody could significantly inhibit spontaneous lympho-
proliferation of HAM/TSP patients without anti-HBZ
response, including CD8+ T cell proliferation. HTLV-1
predominantly infects CD4+ T cells, but CD8+ T cells have
also been shown to carry high proviral loads in HAM/TSP
patients [53] and HBZ mRNA was detectable in both CD4
+ and CD8+ T cells isolated from HAM/TSP patients (data
not shown). It remains to be defined how HBZ-specific
antibody inhibits CD8+ T cell proliferation in HAM/TSP
patients. However, since humoral immunity is not limited
to extracellular viral recognition but can neutralize a virus
even within the cytosol of infected cells [54], HBZ-specific
antibodies might therefore be able to interact with HBZ
within HTLV-I infected cells. Further experiments includ-
ing the nuclear retention and translation of HBZ mRNAs
and the involvement of HBZ in lymphoproliferation of
HAM/TSP patients would support these conclusions. Al-
though we did not detect an inhibitory effect of HBZ-
specific antibody on CD4+ T cell proliferation because this
subset exhibits less spontaneous proliferation than CD8+
cells, the presence of antibody responses against HBZ was
associated with less CD4+ T cell activation (frequency of
CD25+ T cell subset) in HAM/TSP patients with anti-
HBZ antibody responses. In CD8+ T cells, the frequency
of CD25+ cells was also less in HAM/TSP patients with
anti-HBZ antibody responses and approached statistical
significance. These results demonstrated that HBZ-specific
antibody responses have potentially beneficial roles in sup-
pressing T cell activation in HAM/TSP patients. Since T
cell activation is regulated through intricate molecular and
immunological signaling networks, it will be of interest to
determine how HBZ-specific antibody suppresses T cell ac-
tivation of HAM/TSP patients.
Conclusions
In summary, this is the first report demonstrating the
presence of a humoral immune response to HBZ in the
context of HTLV-1-infection. Characterization of theimmune response against each of the HTLV-1 viral anti-
gens will further improve our knowledge of virus-host




The subjects for the present analysis were participants
in research studies conducted at the National Institute
of Neurological Disorders and Stroke (NINDS) at NIH,
or the University of the West Indies (UWI), Kingston,
Jamaica in collaboration with the National Cancer Insti-
tute (NCI), Bethesda, MD. Informed consent was writ-
ten and obtained from each subject in accordance with
the Declaration of Helsinki.
NIH subjects: Serum samples were obtained from a
total of 92 subjects, including 25 HTLV-1-seronegative
donors (NDs), 12 ACs and 55 HAM/TSP patients. CSF
samples were obtained from 5 HAM/TSP patients. The
study was reviewed and approved by the National Insti-
tute of Neurological Disorders and Stroke Institutional
Review Board.
Jamaican subjects: All serum and plasma samples
from study subjects were previously tested for HTLV by
ELISA (Dupont, Wilmington DE) or EIA (Vironostika,
Organo Teknika, Durham, NC); seropositive samples
were previously tested by Western blot (Cambridge Bio-
tech, Rockville MD or Genelabs Diagnostics HTLV-1
blot 2.4, Singapore). Serum/plasma samples were
obtained from a total of 344 subjects, including 73 NDs,
133 HTLV-1 seropositive ACs, 89 ATL patients and 49
HAM/TSP patients. The NDs and ACs were selected
from participants in a nested case–control study of risk
factors for HTLV-1 seropositivity conducted among
foodhandlers from Kingston and Clarendon parishes in
1987–1988 [55]. Samples from these subjects were
obtained from either that study, or a previous seropreva-
lence study that these subjects participated in between
1985–1986 [56]. ATL subjects were selected from among
ATL cases identified through an island-wide disease regis-
try and referred to the UWI clinic in 1984–2006 [36]. For
the current analysis, we randomly selected 30 subjects
from each of the two ATL subtypes (acute and lymphoma)
and 29 subjects from the ATL subtype (chronic) for a total
of 89 subjects. In Jamaica, acute ATL is the most common
subtype, accounting for 47% of ATL patients. The lymph-
oma and chronic subtypes occur in 27% and 21% of ATL
patients, respectively. A fourth subtype, smoldering ATL,
is uncommon, occurring in only 6% of Jamaican ATL
patients (and were not included in this analysis) [36].
HAM/TSP subjects were selected among participants in
an island-wide registry conducted in 1988–1998 [57]. The
study protocols followed the human experimentation
guidelines of the US Department of Health and Human
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the NCI and UWI.
LIPS assay
HTLV-1 cDNA clones for Gag, Env and Tax were inserted
into pREN2, a mammalian Renilla luciferase expression
vector, and generated as previously described [30]. A
HTLV-1 cDNA clone for HBZ (AU1), which is a spliced
form, was kindly gifted from Dr. Genoveffa Franchini
(NCI, NIH, Bethesda, MD). Primers used for generation
of HBZ/pREN2: HBZ-LIPS-F: 5′-gag gga tcc gcg gcc tca
ggg ctg ttt cga t-3′; HBZ-LIPS-R: 5′-ctc tct aga tta ttg caa
cca cat cgc ctc cag-3′. Each mammalian expression vector
with the HTLV-1 gene was transfected into 293T cells
using FuGENEW6 transfection reagent (Roche Diagnostics,
Indianapolis, IN) [31]. The LIPS assay was performed as
previously described [31]. Serum, plasma or CSF samples
were diluted to 1:100. All anti-HBZ data from independ-
ent experiments were normalized using the LU values of
positive control rabbit anti-HBZ serum. Cut-off values for
anti-HBZ immunoreactivity were defined as an HBZ-LIPS
antibody response that was in the 100 percentile of the
values of the ND group (6853 LU). All anti-Gag, anti-Env
and anti-Tax data from independent experiments were
normalized using the LU values of positive control serum
from a well-known HAM/TSP patient.
HTLV-1 proviral DNA load
HTLV-1 proviral DNA load was measured using Viia™ 7
Real-Time PCR system (Applied Biosystems, Carlsbad,
CA) as previously described [58]. DNA was extracted
from PBMCs of HAM/TSP patients using QIAamp
DNA Blood Mini Kit (QIAGEN, Germantown, MD),
and 100ng of the sample DNA solution per well was
analyzed by this system. All samples were performed in
triplicate.
HTLV-1 HBZ mRNA detection
Total RNAs were extracted from PBMCs of HAM/TSP
patients by RNeasyW Mini Kit (QIAGEN), according to
the manufacture’s instruction. 85 ng of total RNA was
used to be converted into cDNA and amplified in a one
step reaction using TaqManW RNA-to-Ct™ 1-Step Kit
(Applied Biosystems) according to the manufacturer’s
instructions. The sequences of primers and probe for
HBZ mRNA detection were as follows: (forward) 5′-aga
acg cga ctc aac cgg-3′, (reverse) 5′-tga cac agg caa gca
tcg a-3′ and (probe) 5′-tgg atg gcg gcc tca ggg ct-3′. As
the probe for HBZ surrounded the splice junction site of
HBZ mRNA, this method detected only the spliced form
of HBZ. Hypoxanthine-guanine phosphoribosyltransfer-
ase (HPRT) was detected as an endogenous control. The
HTLV-1-infected cell line MT-2 was used as a calibrator
sample and the level of HBZ mRNA expression was thencalculated using the comparative CT method on ViiA™
7 software (Applied Biosystems).
Generation of IgG+ memory B cells
IgG+ memory B cells were isolated from PBMCs using
IgG+ memory B cells isolation kit (Miltenyi, Bergisch
Gladbach, Germany). The memory B cells were seeded
at 50 cells per wells in 96 U-bottom microplates in
complete medium containing 2 ng of ODN 2006 (Invi-
vogen, San Diego, CA) in the presence of EBV (30%
supernatant of B95.8 cells) and irradiated allogeneic
mononuclear cells (20,000 per well). After culture for
two weeks, the production of HTLV-1-specific anti-
bodies was screened in the culture supernatants of
immortalized memory B cells using LIPS assay. The cul-
ture supernatants of memory B cells producing anti-
HBZ were collected and stored at −807C until use.
After desalting, HBZ-specific IgG was isolated using
HiTrap protein G columns (GE Healthcare, Uppsala,
Sweden) and concentrated by AmiconW Ultra centrifugal
filters (Millipore, Ireland).
Western blot
The production of HBZ-specific antibody from memory
B cell culture was further determined by western blot.
The nuclear proteins were extracted from HTLV-1
-infected (MT-2 and HUT102) and uninfected cell lines
(Jurkat and MOLT-3), 293T cells and HBZ/pRen2-trans-
fected 293T cells using Nuclear extract kit (Active Motif,
Carlsbad, CA). Protein concentration was determined
using Quick Start Bradford Protein Assay (BioRad,
Hercules, CA). From each protein sample, 50 μg was
electrophoresed through a NuPAGEW 4-12% Bis–Tris
gel (Invitrogen). The gel was transferred to a nitrocellur-
ose membrane (Invitrogen). After blocking with 3% BSA
in TBS, the membrane was probed with B cell culture
supernatant or rabbit anti-HBZ serum as positive control,
and then probed with horseradish peroxidase-conjugated
goat anti-human IgG (Santa Cruz Biotechnology, Santa
Cruz, CA). The membrane was visualized by chemilumin-
escence using SuperSignalW West Pico Chemiluminescent
substrate (Thermo Scientific, Rockford, IL) and analyzed
the profile on Kodak digital science™ 1D image analysis
software (Kodak, Rochester, NY). The intensity of HBZ
proteins detected by B cell culture supernatant or rabbit
anti-HBZ serum was normalized by the intensity of
β-actin.
Flow cytometry
For analysis of peripheral blood lymphocyte populations,
patients’ PBMCs were stained with CD3, CD4, CD8 and
CD25 (all from BD Biosciences, San Jose, CA). Flow
cytometric analysis was performed using a LSR II (BD
Enose-Akahata et al. Retrovirology 2013, 10:19 Page 11 of 13
http://www.retrovirology.com/content/10/1/19Biosciences). The data were analyzed using FlowJo soft-
ware (Tree Star, San Carlos, CA).Lymphoproliferation assay
PBMCs were labeled with CFSE (CellTrace™ CFSE cell
proliferation kit; Invitrogen) according to the manufac-
turer’s instruction, and plated at 2×105 cells/well into 96
U-bottom microplates with 1 μg/ml of HBZ-specific IgG
or human IgG as control. After culture for 6 days, the
cells were stained with antibodies against CD3, CD4 and
CD8 (all from BD Biosciences). The data were acquired
on an LSRII flow cytometer (BD Biosciences).Statistical analysis
Race, gender and age information for each patient were
organized into matrix form with the anti-HBZ data
generated for each patient. Using Prism (GraphPad
software), the Mann–Whitney Test was used to com-
pare: the age distributions among the groups, anti-HBZ
antibody levels between patient study groups (i.e.,
“ND”, “AC”, “ATL”, “HAM/TSP”), anti-HBZ antibody
levels between ATL subtypes (i.e., “Acute”, “Chronic”,
“Lymphoma”), anti-Gag, anti-Env and anti-Tax antibody
levels between anti-HBZ positive and anti-HBZ nega-
tive groups, proviral DNA loads and HBZ mRNA ex-
pression between anti-HBZ positive and anti-HBZ
negative groups, and frequencies of CD4+CD25+ and
CD8+CD25+ T cells of NDs, HAM/TSP patients with
and without antibody responses for HBZ. Still within
Prism, the Chi-Square Test was used to compare the
gender and racial distributions among the groups, num-
bers of anti-HBZ positive and anti-HBZ negative sub-
jects between study groups and separately again to
compare numbers of anti-HBZ positive and anti-HBZ
negative patients between ATL subtypes. Again in
Prism, Wilcoxson matched-pairs signed rank test was
used to evaluate the inhibitory effects of HBZ-specific
antibody on spontaneous lymphoproliferation in PBMCs
of HAM/TSP patients. Lastly in Prism, Spearman’s correl-
ation was used to evaluate both the association between
anti-HBZ antibody levels and proviral DNA loads and the
association between anti-HBZ antibody levels and HBZ
mRNA expression. Using the statistical programming lan-
guage “R” (http://www.r-project.org/), anti-HBZ data was
log (base = 2) transformed then fit via the Four-Way Ana-
lysis of Variance (ANOVA) model with interactions; using
race, gender, age and patient study group as the factors.
Per race, patients were coded “Caucasian-descent”,
“African-descent”, or “other”. Per gender, subjects were
coded “male” or “female”. Per age, subjects were coded by
quartiles as “young”, “young to middle-age”, “middle-age
to senior”, or “senior”. Post-hoc testing was accomplished
using the Tukey’s Honest Significant Difference method.Competing interests
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